Evidence map›Paper›PMID 7812631›Full record

ArticleBritish journal of pharmacology1994

Vasoconstrictor endothelin receptors characterized in human renal artery and vein in vitro.

J J Maguire, R E Kuc, G O'Reilly, A P Davenport

Open access · bronzeAbstract read
In one paragraph

Article in British journal of pharmacology, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 66 citations in OpenAlex.

  1. Trial
  2. Article
  3. Endothelin 2: a key player in ovulation and fertility.Reproduction (Cambridge, England) · 2022
    Review
  4. Endothelin.Pharmacological reviews · 2016
    Review
  5. Endothelin receptors and their antagonists.Seminars in nephrology · 2015
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Endothelin receptors in human coronary artery and aorta.British journal of pharmacology · 1996
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

J J MaguireClinical Pharmacology Unit, University of Cambridge, Addenbrooke's Hospital.
R E Kuc
G O'Reilly
A P Davenport
University of Cambridge · GBAddenbrooke's Hospital · GB

Funding

Wellcome Trust
6 · The paper itself

Abstract

1. We have identified the endothelin receptors present in the media of human main stem renal artery and vein and characterized the subtypes mediating vasoconstriction in these blood vessels in vitro. 2. Messenger RNA encoding both ETA and ETB receptors was identified in the smooth muscle layer of human renal artery and vein by reverse transcriptase-polymerase chain reaction assay. In cryostat-cut cross-sections of both vessels autoradiographical visualisation suggested a majority of ETA receptors. Intense binding was obtained to the non-selective ligand [125I]-ET-1 and the ETA-selective [125I]-PD151242 but only weak labelling of sites by the ETB-selective [125I]-BQ3020. 3. ET-1 potently constricted renal artery and vein preparations with EC50 values of 4.06 nM and 1.00 nM, respectively. Sarafotoxin 6b was approximately ten times less potent than ET-1 with EC50 values of 36.3 nM and 13.8 nM respectively. In the renal artery, ET-3 and sarafotoxin 6c showed little or no activity up to 300 nM. Responses to these peptides were more variable in the renal vein. Preparations from three individuals did not respond to ET-3 but in three further cases, although ET-3 was much less potent than ET-1, full dose-response curves were obtained. S6c elicited dose-related contractions in vein preparations from 5/6 individuals and although more potent than ET-1, the maximum response was 30-60% of that obtained to ET-1. 4. ET-1-induced vasoconstriction of renal artery and vein was antagonized by the ETA-selective, BQ123 (3-10 microM). The dose-response curves to ET-1 were displaced in a parallel rightward fashion with no attenuation of the maximum responses. pA2 values were estimated to be 6.8 +/- 0.1 and 6.8 +/- 0.4 for artery and vein respectively.5. These data suggest that mRNA encoding both ETA and ETB receptors is present in the media of human main stem renal artery and vein. However, autoradiographical studies indicate that the majority of ET receptors expressed are of the ETA subtype. The relative potencies of ET-1 and ET-3 as vasoconstrictors of renal blood vessels in vitro is consistent with this being an ETA-mediated response,and therefore whilst responses to S6c indicate that constrictor ETB receptors may be present in renal veins from some individuals these are likely to be of less importance in these blood vessels.

Indexed as

AdultAgedAmino Acid SequenceAutoradiographyBase SequenceEndothelin Receptor AntagonistsFemaleHumansIn Vitro TechniquesMaleMiddle AgedMolecular Sequence DataPeptides, CyclicPolymerase Chain ReactionReceptors, EndothelinRenal Arterycyclo(Trp-Asp-Pro-Val-Leu)Endothelin Receptor AntagonistsPeptides, CyclicReceptors, EndothelinRNA, Messengersarafotoxins s6Vasoconstrictor AgentsViper Venoms

Identifiers

PMID7812631
PMCPMC1510060
OpenAlexW1976580147

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.